Efficacy of Subantimicrobial Dose Doxycycline for Moderate-to-Severe and Active Graves' Orbitopathy

Miaoli Lin, Yuxiang Mao, Siming Ai, Guangming Liu, Jian Zhang, Jianhua Yan, Huasheng Yang, Aimin Li, Yusha Zou, Dan Liang, Miaoli Lin, Yuxiang Mao, Siming Ai, Guangming Liu, Jian Zhang, Jianhua Yan, Huasheng Yang, Aimin Li, Yusha Zou, Dan Liang

Abstract

Aim. To study the efficacy and safety of subantimicrobial dose (SD) doxycycline(50 mg/d) in patients with active and moderate-to-severe Graves' orbitopathy (GO). Methods. Thirteen patients with active and moderate-to-severe GO received once daily oral doxycycline (50 mg/d) for 12 wk. Treatment response at 24 wk was used as the primary outcome, measured by a composite of improvement in Clinical Activity Score (CAS), diplopia, motility, soft tissue swelling, proptosis, and eyelid aperture. Secondary outcome was the change of quality of life score (QoL, including visual functioning subscale and appearance subscale). Adverse events were also recorded. Results. Overall improvement was noted in eight out of 13 patients (61.5%, 95% CI 31.6%-86.1%). Both CAS and soft tissue swelling significantly ameliorated in eight patients at 24 wk. Five patients (38.5%) had improvement in ocular motility of ≥8 degrees. Eyelid aperture (46.2%) also decreased remarkably. For QoL, a significant improvement in appearance subscale (P = 0.008) was noted during the study, whereas no difference was observed in visual functioning subscale (P = 0.21). Two patients reported mild stomachache at 12 wk. Conclusions. SD doxycycline appears to be effective and safe for the treatment of active and moderate-to-severe GO. It might serve as a new promising therapeutic strategy for GO. This trial is registered with NCT01727973.

Figures

Figure 1
Figure 1
Representative example of patients status at baseline and at 24 wk after the start of treatment. (a) (baseline) and (b) (24 wk) showed that soft tissue involvements and redness of conjunctiva were remarkably improved in a female at 24 wk. (c) (baseline) and (d) (24 wk) showed the improvement of eyelid aperture, lid lag, and elevation in a male treated by doxycycline.

References

    1. Douglas R. S., Gupta S. The pathophysiology of thyroid eye disease: implications for immunotherapy. Current Opinion in Ophthalmology. 2011;22(5):385–390. doi: 10.1097/ICU.0b013e3283499446.
    1. Piantanida E., Tanda M. L., Lai A., Sassi L., Bartalena L. Prevalence and natural history of Graves' orbitopathy in the XXI century. Journal of Endocrinological Investigation. 2013;36(6):444–449. doi: 10.3275/8937.
    1. Tanda M. L., Piantanida E., Liparulo L., et al. Prevalence and natural history of graves' orbitopathy in a large series of patients with newly diagnosed graves' hyperthyroidism seen at a single center. The Journal of Clinical Endocrinology & Metabolism. 2013;98(4):1443–1449. doi: 10.1210/jc.2012-3873.
    1. Kahaly G. J., Pitz S., Hommel G., Dittmar M. Randomized, single blind trial of intravenous versus oral steroid monotherapy in graves' orbitopathy. Journal of Clinical Endocrinology and Metabolism. 2005;90(9):5234–5240. doi: 10.1210/jc.2005-0148.
    1. Bartalena L., Krassas G. E., Wiersinga W., et al. Efficacy and safety of three different cumulative doses of intravenous methylprednisolone for moderate to severe and active Graves' orbitopathy. The Journal of Clinical Endocrinology and Metabolism. 2012;97(12):4454–4463. doi: 10.1210/jc.2012-2389.
    1. Zang S., Ponto K. A., Kahaly G. J. Intravenous glucocorticoids for graves' orbitopathy: efficacy and morbidity. Journal of Clinical Endocrinology and Metabolism. 2011;96(2):320–332. doi: 10.1210/jc.2010-1962.
    1. Prummel M. F., Mourits M. P., Blank L., Berghout A., Koornneef L., Wiersinga W. M. Randomised double-blind trial of prednisone versus radiotherapy in Graves' ophthalmopathy. The Lancet. 1993;342(8877):949–954. doi: 10.1016/0140-6736(93)92001-A.
    1. Marcocci C., Watt T., Altea M. A., et al. Fatal and non-fatal adverse events of glucocorticoid therapy for Graves' orbitopathy: a questionnaire survey among members of the European Thyroid Association. European Journal of Endocrinology. 2012;166(2):247–253. doi: 10.1530/EJE-11-0779.
    1. Zangi S., Ponto K. A., Pitz S., Kahaly G. J. Dose of intravenous steroids and therapy outcome in Graves' orbitopathy. Journal of Endocrinological Investigation. 2011;34(11):876–880. doi: 10.1007/BF03346732.
    1. Khanna D., Chong K. K. L., Afifiyan N. F., et al. Rituximab treatment of patients with severe, corticosteroid-resistant thyroid-associated ophthalmopathy. Ophthalmology. 2010;117(1):133.e2–139.e2. doi: 10.1016/j.ophtha.2009.05.029.
    1. Vannucchi G., Campi I., Bonomi M., et al. Rituximab treatment in patients with active Graves' orbitopathy: effects on proinflammatory and humoral immune reactions. Clinical and Experimental Immunology. 2010;161(3):436–443. doi: 10.1111/j.1365-2249.2010.04191.x.
    1. Lindeman J. H. N., Abdul-Hussien H., Van Bockel J. H., Wolterbeek R., Kleemann R. Clinical trial of doxycycline for matrix metalloproteinase-9 inhibition in patients with an abdominal aneurysm doxycycline selectively depletes aortic wall neutrophils and cytotoxic t cells. Circulation. 2009;119(16):2209–2216. doi: 10.1161/CIRCULATIONAHA.108.806505.
    1. del Rosso J. Q., Webster G. F., Jackson M., et al. Two randomized phase III clinical trials evaluating anti-inflammatory dose doxycycline (40-mg doxycycline, USP capsules) administered once daily for treatment of rosacea. Journal of the American Academy of Dermatology. 2007;56(5):791–802. doi: 10.1016/j.jaad.2006.11.021.
    1. Golub L. M., Hsi M. L., Stoner J. A., et al. Subantimicrobial-dose doxycycline modulates gingival crevicular fluid biomarkers of periodontitis in postmenopausal osteopenic women. Journal of Periodontology. 2008;79(8):1409–1418. doi: 10.1902/jop.2008.070623.
    1. Minagar A., Alexander J. S., Schwendimann R. N., et al. Combination therapy with interferon beta-1a and doxycycline in multiple sclerosis: an open-label trial. Archives of Neurology. 2008;65(2):199–204. doi: 10.1001/archneurol.2007.41.
    1. O'Dell J. R., Elliott J. R., Mallek J. A., et al. Treatment of early seropositive rheumatoid arthritis: doxycycline plus methotrexate versus methotrexate alone. Arthritis and Rheumatism. 2006;54(2):621–627. doi: 10.1002/art.21620.
    1. Bostanci N., Akgül B., Tsakanika V., Allaker R. P., Hughes F. J., McKay I. J. Effects of low-dose doxycycline on cytokine secretion in human monocytes stimulated with Aggregatibacter actinomycetemcomitans. Cytokine. 2011;56(3):656–661. doi: 10.1016/j.cyto.2011.08.039.
    1. Emingil G., Gürkan A., Atilla G., Kantarci A. Subantimicrobial-dose doxycycline and cytokine-chemokine levels in gingival crevicular fluid. Journal of Periodontology. 2011;82(3):452–461. doi: 10.1902/jop.2010.100036.
    1. Bahn R. S. Graves' ophthalmopathy. The New England Journal of Medicine. 2010;362(8):726–774. doi: 10.1056/NEJMra0905750.
    1. Smith T. J. Pathogenesis of Graves' orbitopathy: a 2010 update. Journal of Endocrinological Investigation. 2010;33(6):414–421. doi: 10.1007/BF03346614.
    1. Bartalena L., Baldeschi L., Dickinson A., et al. Consensus statement of the European Group on Graves' orbitopathy (EUGOGO) on management of GO. European Journal of Endocrinology. 2008;158(3):273–285. doi: 10.1530/EJE-07-0666.
    1. Bahn R. S., Gorman C. A. Choice of therapy and criteria for assessing treatment outcome in thyroid-associated ophthalmopathy. Endocrinology and Metabolism Clinics of North America. 1987;16(2):391–407.
    1. Hallin E. S., Feldon S. E. Graves' ophthalmopathy: II. Correlation of clinical signs with measures derived from computed tomography. The British Journal of Ophthalmology. 1988;72(9):678–682. doi: 10.1136/bjo.72.9.678.
    1. Dickinson A. J., Perros P. Controversies in the clinical evaluation of active thyroid-associated orbitopathy: use of a detailed protocol with comparative photographs for objective assessment. Clinical Endocrinology. 2001;55(3):283–303. doi: 10.1046/j.1365-2265.2001.01349.x.
    1. van Geest R. J., Sasim I. V., Koppeschaar H. P. F., et al. Methylprednisolone pulse therapy for patients with moderately severe Graves' orbitopathy: a prospective, randomized, placebo-controlled study. European Journal of Endocrinology. 2008;158(2):229–237. doi: 10.1530/EJE-07-0558.
    1. Bartalena L., Marcocci C., Bogazzi F., et al. Relation between therapy for hyperthyroidism and the course of Graves' ophthalmopathy. The New England Journal of Medicine. 1998;338(2):73–78.
    1. Mourits M. P., Van Kempen-Harteveld M. L., García García M. B., Koppeschaar H. P. F., Tick L., Terwee C. B. Radiotherapy for Graves' orbitopathy: randomised placebo-controlled study. Lancet. 2000;355(9214):1505–1509. doi: 10.1016/S0140-6736(00)02165-6.
    1. Marcocci C., Bartalena L., Bogazzi F., Panicucci M., Pinchera A. Studies on the occurrence of ophthalmopathy in Graves' disease. Acta Endocrinologica. 1989;120(4):473–478.
    1. Perros P., Crombie A. L., Matthews J. N. S., Kendall-Taylor P. Age and gender influence the severity of thyroid-associated ophthalmopathy: a study of 101 patients attending a combined thyroid-eye clinic. Clinical Endocrinology. 1993;38(4):367–372. doi: 10.1111/j.1365-2265.1993.tb00516.x.
    1. Bartalena L., Pinchera A., Marcocci C. Management of graves' ophthalmopathy: reality and perspectives. Endocrine Reviews. 2000;21(2):168–199. doi: 10.1210/er.21.2.168.
    1. Ben Simon G. J., Mansury A. M., Schwarcz R. M., Modjtahedi S., McCann J. D., Goldberg R. A. Transconjunctival Müller muscle recession with levator disinsertion for correction of eyelid retraction associated with thyroid-related orbitopathy. The American Journal of Ophthalmology. 2005;140(1):94.e1–94.e7. doi: 10.1016/j.ajo.2005.02.034.
    1. Shih M., Liao S., Kuo K., Smith T. J., Chuang L. Molecular pathology of Müller's muscle in Graves' ophthalmopathy. The Journal of Clinical Endocrinology and Metabolism. 2006;91(3):1159–1167. doi: 10.1210/jc.2005-1877.
    1. Tanda M. L., Bartalena L. Efficacy and safety of orbital radiotherapy for graves' orbitopathy. Journal of Clinical Endocrinology and Metabolism. 2012;97(11):3857–3865. doi: 10.1210/jc.2012-2758.
    1. Walker C., Preshaw P. M., Novak J., Hefti A. F., Bradshaw M., Powala C. Long-term treatment with sub-antimicrobial dose doxycycline has no antibacterial effect on intestinal flora. Journal of Clinical Periodontology. 2005;32(11):1163–1169. doi: 10.1111/j.1600-051X.2005.00840.x.
    1. Monk E., Shalita A., Siegel D. M. Clinical applications of non-antimicrobial tetracyclines in dermatology. Pharmacological Research. 2011;63(2):130–135. doi: 10.1016/j.phrs.2010.10.007.
    1. Rashid M. U., Panagiotidis G., Bäckström T., Weintraub A., Nord C. E. Ecological impact of doxycycline at low dose on normal oropharyngeal and intestinal microflora. International Journal of Antimicrobial Agents. 2013;41(4):352–357. doi: 10.1016/j.ijantimicag.2012.11.014.
    1. Walker C., Puumala S., Golub L. M., et al. Subantimicrobial dose doxycycline effects on osteopenic bone loss: microbiologic results. Journal of Periodontology. 2007;78(8):1590–1601. doi: 10.1902/jop.2007.070015.
    1. Gu Y., Walker C., Ryan M. E., Payne J. B., Golub L. M. Non-antibacterial tetracycline formulations: clinical applications in dentistry and medicine. Journal of Oral Microbiology. 2012;419227

Source: PubMed

スポンサーと協力者

医学的状態

薬物療法

3
購読する